09/01/2026
BPDCN is one of the rarest, most aggressive blood cancers, and its treatment landscape is changing.
AMCP brought together a health system pharmacy leader and one of the trial's investigators to give managed care teams a clear read on what changed and what it means for coverage. On this new episode of Unscripted, Ryan Haumschild, PharmD, MS (Emory) and Naveen Pemmaraju, MD (MD Anderson) break down the FDA approval of pivekimab sunirine-pvzy (PVEK), CADENZA trial results, and where this CD123-directed therapy fits, including its safety, outpatient administration, and role in getting eligible patients to stem cell transplant.
Listen now: https://hubs.li/Q04w8gLT0
Sponsored by AbbVie.